News
Vinay Prasad is back at the FDA after last month's surprise ouster. Will he stay this time?
Vinay Prasad, M.D., has rejoined the FDA, the latest turn in a monthslong stretch of leadership turnover at the agency. | “At the FDA’s request, Dr. Vinay Prasad is resuming leadership of the Center for Biologics Evaluation and Research,
Vinay Prasad is returning to his role overseeing vaccine, gene therapy and blood product regulation at the U.S. Food and Drug ...
Vinay Prasad is once again head of the FDA’s Center for Biologics Evaluation and Research, after Laura Loomer led a campaign ...
Pharmaceutical Technology on MSN12h
Prasad’s shock FDA return reignites regulatory uncertainty
Vinay Prasad resumes leadership at the FDA’s CBER two weeks after he resigned amid cell and gene therapy controversy.
Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA ...
In our Venable FDA Pulse series, we report on critical developments within the Food and Drug Administration (FDA or the Agency) that may affect ...
Vinay Prasad is back at the FDA, and in a position in which grappling with nuance — not always his strong suit — will be the ...
Vinay Prasad is once again head of the FDA’s Center for Biologics Evaluation and Research, after Laura Loomer led a campaign ...
After exiting the FDA less than two weeks ago for unclear reasons, Vinay Prasad is once again director of the Center for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback